Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC

Inclusion Criteria: 1. ECOG performance status≤2； 2. Cytologically or pathologically confirmed stage IV NSCLC ( controlled pleural effusion will be eligible) with active EGFR mutation; 3. Estimated survival time more than 3 months; 4. Age older than 18 years and under 75 years; 5. Adequate bone marrow, hepatic, and renal function;AST and ALT≤2.5 times the highest reference value when not associated with hepatic metastases, or ≤5 times when hepatic metastases occur; 6. Without history of therapy for primary and metastatic disease; 7. With pleural effusion but can be controlled; 8. Asymptomatic bone metastases without treatment; 9. Based on fusion images of 4DCT MIP sketch tumors and lymph nodes, and limit the mean lung dose: V20≤25%，V30≤18%，MLD≤14Gy，V5≤60%; 10. M1a or M1b for metastases, and the number of the distant lesions ≤10； 11. Voluntary to participate in this clinical trial and sign the consent form. Exclusion Criteria: 1. Patients with serious functional damage of important organs; 2. Patients diagnosed adequately with other malignant tumors; 3. Pregnant or lactating women; 4. Patients in an active period of acute or chronic infectious diseases; 5. Patients who are allergic to any drugs or people with allergies; 6. With brain metastases; 7. With bone metastases needing radiotherapy; 8. Patients who participate in other clinical trials concurrently; 9. Uncontrolled pleural effusion which may intervene the radiotherapy to primary tumor in lung; 10. The number of the distant lesions\>10； 11. Patients who are considered not eligible for the trial after evaluation by investigator.